ReviewAdvances in experimental medicine and biology2023
Malignant Glioma.
Review in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Influence of diabetes on survival of patients with glioma: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Single-cell and intercellular communication analyses reveal DLL3 as a key regulator in the glioma tumor microenvironment.Molecular therapy. Nucleic acids · 2026Article
- Associations between migrasome-related genes and long non-coding rnas in glioma and their prognostic relevance to the tumor microenvironment.IBRO neuroscience reports · 2026Article
- A two-stage model combining clinical and delta-radiomics features for prognosis in high-grade gliomas after chemoradiotherapy: a retrospective study.La Radiologia medica · 2026Article
- Plitidepsin induces apoptosis in glioma cells through β-TrCP-mediated ubiquitination and degradation of BMI1.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A dual-wavelength blue laser platform for integrated diagnosis and therapy in glioblastoma: preclinical evidence.Lasers in medical science · 2026Article
- A real-world feasibility and safety study of anlotinib monotherapy in heavily pretreated or temozolomide-ineligible recurrent malignant glioma.Translational cancer research · 2026Article
- Licochalcone a Disrupted Mitochondrial Function to Promote Cuproptosis in Glioblastoma Through Regulating RAS/MAPK Pathway.Applied biochemistry and biotechnology · 2026Article
- KLF15-POU3F4 axis activates PI3K/AKT signaling to promote glioma progression.Translational cancer research · 2026Article
- NPC2 Regulates Glioblastoma Cholesterol Metabolism and Malignant Behavior via GPX4-Linked Ferroptosis.Cell biology international · 2026Article
- RBM15 in diseases: Molecular mechanisms and clinical opportunities from RNA mGenes & diseases · 2026Review
- Development and validation of a preoperative glycolipid metabolism-based nomogram for predicting postoperative recurrence in primary glioma: a retrospective cohort study.Lipids in health and disease · 2026Article
- Cinobufotalin reduces glioblastoma resistance to temozolomide by inhibiting the CCL5-mediated PI3K/Akt/mTOR signaling pathway.Translational cancer research · 2026Article
- Article
- Formyl Peptide Receptor-2-Suppressed Autophagy Promotes the Migration and Invasion of Human Glioblastoma Cells Through PI3K/Akt Signaling.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- LncRNA FOXP4-AS1 promotes glioma cell proliferation, metastasis, and glycolysis via the miR-136-5p/ADCYAP1R1 axis.Functional & integrative genomics · 2026Article
- Liquid biopsy of plasma and urinary CfDNA differentiates glioma recurrence from radiation brain necrosis in preclinical models.Scientific reports · 2026Article
- Superior mucoepidermoid carcinoma detection with ⁶⁸Ga-FAPI PET/CT reflects FAP-α expression and MAML2 fusion status.Scientific reports · 2026Article
- Stratified and Quantified Score Construction of Low-Grade Glioma Samples Based on TP53 Signaling Pathway.BioMed research international · 2026Article
- Increased expression of SMAD5-AS1 in glioma is associated with patient prognosis and immunity.International journal of clinical and experimental pathology · 2026Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This chapter provides a comprehensive overview of malignant gliomas, the most common primary brain tumor in adults. These tumors are varied in their cellular origin, genetic profile, and morphology under the microscope, but together they share some of the most dismal prognoses of all neoplasms in the body. Although there is currently no cure for malignant glioma, persistent efforts to improve outcomes in patients with these tumors have led to modest increases in survival, and researchers worldwide continue to strive toward a deeper understanding of the factors that influence glioma development and response to treatment. In addition to well-established epidemiology, clinical manifestations, and common histopathologic and radiologic features of malignant gliomas, this section considers recent advances in molecular biology that have led to a more nuanced understanding of the genetic changes that characterize the different types of malignant glioma, as well as their implications for treatment. Beyond the traditional classification of malignant gliomas based on histopathological features, this chapter incorporates the World Health Organization's 2016 criteria for the classification of brain tumors, with special focus on disease-defining genetic alterations and newly established subcategories of malignant glioma that were previously unidentifiable based on microscopic examination alone. Traditional therapeutic modalities that form the cornerstone of treatment for malignant glioma, such as aggressive surgical resection followed by adjuvant chemotherapy and radiation therapy, and the studies that support their efficacy are reviewed in detail. This provides a foundation for additional discussion of novel therapeutic methods such as immunotherapy and convection-enhanced delivery, as well as new techniques for enhancing extent of resection such as fluorescence-guided surgery.
Indexed as
Identifiers
37452933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.